Stratification of Fabry Mutations in Clinical Practice: a Closer Look at α-galactosidase A-3D Structure
Overview
Affiliations
Background: Fabry disease (FD) is an X-linked lysosomal storage and multi-system disorder due to mutations in the α-galactosidase A (α-GalA) gene. We investigated the impact of individual amino acid exchanges in the α-GalA 3D-structure on the clinical phenotype of FD patients.
Patients And Methods: We enrolled 80 adult FD patients with α-GalA missense mutations and stratified them into three groups based on the amino acid exchange location in the α-GalA 3D-structure: patients with active site mutations, buried mutations and other mutations. Patient subgroups were deep phenotyped for clinical and laboratory parameters and FD-specific treatment.
Results: Patients with active site or buried mutations showed a severe phenotype with multi-organ involvement and early disease manifestation. Patients with other mutations had a milder phenotype with less organ impairment and later disease onset. α-GalA activity was lower in patients with active site or buried mutations than in those with other mutations (P < 0.01 in men; P < 0.05 in women) whilst lyso-Gb3 levels were higher (P < 0.01 in men; <0.05 in women).
Conclusions: The type of amino acid exchange location in the α-GalA 3D-structure determines disease severity and temporal course of symptom onset. Patient stratification using this parameter may become a useful tool in the management of FD patients.
Dorsal root ganglion magnetic resonance imaging biomarker correlations with pain in Fabry disease.
Schindehutte M, Weiner S, Klug K, Holzli L, Nauroth-Kress C, Hessenauer F Brain Commun. 2024; 6(3):fcae155.
PMID: 38751382 PMC: 11095551. DOI: 10.1093/braincomms/fcae155.
Small fibre neuropathy in Fabry disease: a human-derived neuronal disease model and pilot data.
Klein T, Gruner J, Breyer M, Schlegel J, Schottmann N, Hofmann L Brain Commun. 2024; 6(2):fcae095.
PMID: 38638148 PMC: 11024803. DOI: 10.1093/braincomms/fcae095.
Breyer M, Gruner J, Klein A, Finke L, Klug K, Sauer M Mol Genet Metab Rep. 2024; 38:101029.
PMID: 38469097 PMC: 10926200. DOI: 10.1016/j.ymgmr.2023.101029.
Consolato F, De Fusco M, Schaeffer C, Pieruzzi F, Scolari F, Gallieni M Mol Genet Metab Rep. 2022; 33:100926.
PMID: 36345359 PMC: 9636577. DOI: 10.1016/j.ymgmr.2022.100926.
X-chromosomal inactivation patterns in women with Fabry disease.
Wagenhauser L, Rickert V, Sommer C, Wanner C, Nordbeck P, Rost S Mol Genet Genomic Med. 2022; 10(9):e2029.
PMID: 35971858 PMC: 9482401. DOI: 10.1002/mgg3.2029.